Article Details

Survey of Clinicians: Lower Cost of Biosimilars is the Main Driver of Treatment Choice in IBD

Retrieved on: 2024-09-07 11:06:02

Tags for this article:

Click the tags to see associated articles and topics

Survey of Clinicians: Lower Cost of Biosimilars is the Main Driver of Treatment Choice in IBD. View article details on hiswai:

Excerpt

Infliximab and adalimumab, both monoclonal antibodies targeting tumor necrosis factor (TNF)-α, were the earliest biologic therapies indicated for ...

Article found on: www.centerforbiosimilars.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up